BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26835302)

  • 1. Pediatric Hodgkin Lymphoma: on the road to a 'radiotherapy-free' cure rate?-Commentary on a report on final results of the Multinational Trial GPOH-HD95.
    Corazzelli G
    Transl Pediatr; 2013 Jul; 2(3):120-3. PubMed ID: 26835302
    [No Abstract]   [Full Text] [Related]  

  • 2. Omitting or reducing radiotherapy in childhood or adolescence Hodgkin Lymphoma.
    Vassilakopoulos TP; Boutsikas G; Papadakis V
    Transl Pediatr; 2013 Jul; 2(3):126-30. PubMed ID: 26835304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
    Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G
    J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of central review and central therapy planning on the treatment of children and adolescents with Hodgkin lymphoma.
    Lüders H; Rühl U; Marciniak H; Haerting J; Claviez A; Mann G; Schellong G; Wickmann L; Dörffel W
    Eur J Cancer; 2014 Jan; 50(2):425-33. PubMed ID: 24157256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
    Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodeficiency and Hodgkin's disease: treatment and outcome in the DAL HD78-90 and GPOH HD95 studies.
    Niehues T; Schellong G; Dörffel W; Bucsky P; Mann G; Körholz D; Göbel U
    Klin Padiatr; 2003; 215(6):315-20. PubMed ID: 14677095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial.
    Mauz-Körholz C; Landman-Parker J; Balwierz W; Ammann RA; Anderson RA; Attarbaschi A; Bartelt JM; Beishuizen A; Boudjemaa S; Cepelova M; Claviez A; Daw S; Dieckmann K; Fernández-Teijeiro A; Fosså A; Gattenlöhner S; Georgi T; Hjalgrim LL; Hraskova A; Karlén J; Kluge R; Kurch L; Leblanc T; Mann G; Montravers F; Pears J; Pelz T; Rajić V; Ramsay AD; Stoevesandt D; Uyttebroeck A; Vordermark D; Körholz D; Hasenclever D; Wallace WH
    Lancet Oncol; 2022 Jan; 23(1):125-137. PubMed ID: 34895479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial.
    Mauz-Körholz C; Hasenclever D; Holzendorf V; Bernstädt M; Jürgens H; Burdach S; Eggert A; Berthold F; Müller HL; Frühwald MC; Klingebiel T; Metzler M; Körholz D
    Leuk Lymphoma; 2015 May; 56(5):1308-14. PubMed ID: 25204374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial.
    Rühl U; Albrecht M; Dieckmann K; Lüders H; Marciniak H; Schellenberg D; Wickmann L; Dörffel W
    Int J Radiat Oncol Biol Phys; 2001 Dec; 51(5):1209-18. PubMed ID: 11728679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma.
    Metzger ML; Weinstein HJ; Hudson MM; Billett AL; Larsen EC; Friedmann A; Howard SC; Donaldson SS; Krasin MJ; Kun LE; Marcus KJ; Yock TI; Tarbell N; Billups CA; Wu J; Link MP
    JAMA; 2012 Jun; 307(24):2609-16. PubMed ID: 22735430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
    Kampers J; Orjuela-Grimm M; Schober T; Schulz TF; Stiefel M; Klein C; Körholz D; Mauz-Körholz C; Kreipe H; Beier R; Maecker-Kolhoff B
    Leuk Lymphoma; 2017 Mar; 58(3):633-638. PubMed ID: 27685149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group.
    Mauz-Körholz C; Lange T; Hasenclever D; Burkhardt B; Feller AC; Dörffel W; Kluge R; Vordermark D; Körholz D
    Klin Padiatr; 2015 Nov; 227(6-7):314-21. PubMed ID: 26356319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years].
    Dörffel W; Albrecht M; Lüders H; Marciniak H; Parwaresch R; Schwarze EW; Trauzeddel R; Havers W; Henze G; Janka-Schaub G; Mann G; Niemeyer C; Pötter R; Schellong G; Selle B; Treuner J; Rühl U
    Klin Padiatr; 1998; 210(4):212-9. PubMed ID: 9743955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies.
    Körholz D; Claviez A; Hasenclever D; Kluge R; Hirsch W; Kamprad F; Dörffel W; Wickmann L; Papsdorf K; Dieckmann K; Kahn T; Mauz-Körholz C; Dannenberg C; Pötter R; Brosteanu O; Schellong G; Sabri O
    Klin Padiatr; 2004; 216(3):150-6. PubMed ID: 15175959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current approaches to the management of pediatric Hodgkin lymphoma.
    Freed J; Kelly KM
    Paediatr Drugs; 2010 Apr; 12(2):85-98. PubMed ID: 20218745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
    Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
    Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Adolescent Low-Risk Classical Hodgkin Lymphoma: Which Chemotherapy Backbone Gives the Best Chance of Omitting Radiotherapy Safely.
    Algiraigri AH; Essa MF
    J Adolesc Young Adult Oncol; 2016 Mar; 5(1):2-7. PubMed ID: 26812449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
    Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
    J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook.
    Dörffel W; Lüders H; Rühl U; Albrecht M; Marciniak H; Parwaresch R; Pötter R; Schellong G; Schwarze EW; Wickmann L
    Klin Padiatr; 2003; 215(3):139-45. PubMed ID: 12838937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
    Metzger ML; Link MP; Billett AL; Flerlage J; Lucas JT; Mandrell BN; Ehrhardt MJ; Bhakta N; Yock TI; Friedmann AM; de Alarcon P; Luna-Fineman S; Larsen E; Kaste SC; Shulkin B; Lu Z; Li C; Hiniker SM; Donaldson SS; Hudson MM; Krasin MJ
    J Clin Oncol; 2021 Jul; 39(20):2276-2283. PubMed ID: 33826362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.